PHAARMASIA LTD. (PHRMASI) Fair Value & Analysis

Healthcare · IN · Market cap ₹677M

A strong business, screening 91% undervalued on our models.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The rarer combination: high quality (76/100) AND below fair value. That earns a closer look rather than a quick verdict.
• The price is below even our cautious bear case (₹109.07). The market is more pessimistic than our downside scenario.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.

How to read this chart

60‑month range ₹21.25 – ₹129.20 · fair‑value band ₹109.07 – ₹181.79 · the ₹76.00 price screens below the ₹145.43 fair value. Dashed = 300-day average. As of Aug 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

PHAARMASIA LTD. (PHRMASI) currently trades at ₹76.00, while our model-based Fair Value estimate is ₹145.43, implying the stock looks roughly 91.4% undervalued today. The Quality Score stands at 76/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, PHAARMASIA LTD. generated revenue of ₹472M at a net margin of 37.2%. Revenue grew 42.4% year over year. It earns a return on equity of 114.0%. Net debt stands at ₹8.0M. Fundamentals as of Aug 19, 2026

Our scenario range runs from ₹109.07 (bear case) to ₹181.79 (bull case); at ₹76.00, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 192% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 91%, PHRMASI screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹609.16) versus Economic Profit (₹16.97). Highest evidence: ROIC Compounder (72).

Key figures & financial health

Quality Score breakdown

About the company

Phaarmasia Limited manufactures and sells oral contraceptive pills and iron tablets in India. The company offers hormone products, including mifepristone and misoprostaol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, …

Full company description

Phaarmasia Limited manufactures and sells oral contraceptive pills and iron tablets in India. The company offers hormone products, including mifepristone and misoprostaol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, fluoxymesterone, liothyronine sodium, chlorodehydromethyltestosterone, liothyronine sodium, oxandrolone tablets, testosterone cypionate, methenolone enanthate, drostanolone, testosterone, trenbolone, and stanozolol cypionate injections. It provides herbal products, such as herbal toothpaste, cough and sore throat reliver, and mouth ulcer gel under the Smyle brand name. Phaarmasia Limited was incorporated in 1981 and is based in Hyderabad, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

PHAARMASIA LTD. reported revenue of ₹472M in FY2026 versus ₹172M in FY2022, a compound +28.7%/yr. Reported net income was ₹176M in FY2026.

Watch PHRMASI: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 639 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.